ArticleCardiorenal medicine2025
Global Longitudinal Strain Correlates Poorly with Mortality in People with Diabetes Mellitus and Receiving Haemodialysis.
Article in Cardiorenal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elevated Serum Nardilysin Is Inversely Associated with Cardiovascular Disease in Kidney Transplant Recipients.Kidney & blood pressure research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHaemodialysis (HD) is a life-sustaining treatment for individuals with end-stage kidney disease. However, the risk of mortality remains significantly higher compared to the general population, even when matched for age and sex. Global longitudinal strain (GLS), derived from speckle tracking echocardiography, has shown promise as a predictor of mortality in HD patients. However, its prognostic utility in patients with multiple cardiovascular risk factors such as diabetes mellitus (DM) and receiving HD remains unclear. This study aimed to evaluate the prognostic value of GLS in HD patients, with and without DM.
methodsThis prospective study was a long-term follow-up extension study of an earlier published study that investigated a cohort of HD patients from a single centre with a comprehensive cardiovascular imaging protocol. All patients had an echocardiography with the use of speckle tracking software to determine GLS. Patients were divided into group A (with DM) and group B (without DM). Patients were followed up until death, major adverse cardiovascular events, transplantation, or the censoring date (29 February 2024). Statistical analyses were performed using univariate and multivariate Cox proportional hazards models.
resultsA total of 184 patients receiving HD were included in the analysis. Patients with DM (group A) had significantly higher all-cause mortality (ACM) (47.1% vs. 20.7%, p < 0.001) and a lower chance of receiving a kidney transplant (13.2% vs. 43.1%, p < 0.001). In group A, GLS did not predict ACM, whereas in group B, a GLS cut-off of -15.76% correlated with higher 5-year ACM (p = 0.036). Left ventricular ejection fraction (LVEF) was a significant predictor of ACM in group A (HR 0.98; p = 0.036).
conclusionGLS is a poor predictor of adverse outcomes in HD patients with DM, likely due to their high cardiovascular risk. In contrast, GLS was a significant predictor of mortality in non-diabetic HD patients. LVEF may be a more reliable prognostic indicator in high-risk diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.